SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced an exclusive worldwide licensing agreement with GSK…

HUTCHMED (China) Ltd · 6-K filed Sep 3, 2026 at 06:04 ET

At the news

BULLISHIMPACT 7/10

6-K filed Sep 3, 2026 at 06:04 ET

HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) for colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment and up to $1.295 billion in total milestones plus tiered royalties, with HUTCHMED retaining rights in Greater China. This is a major non-dilutive validation of HUTCHMED's ATTC platform and provides significant near-term cash, though the asset is still pre-clinical with Phase I starting H2 2026.

  • HUTCHMED licensed HMPL-A830 (KRAS-EGFR ATTC) to GSK for ex-China rights.
  • Upfront payment of $110 million; total potential milestones up to $1.295 billion plus tiered royalties.
  • HUTCHMED retains full rights in Mainland China, Hong Kong, Macau, and Taiwan.
  • GSK gets right of first negotiation on one earlier-stage ATTC candidate.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access